Inaedis
Inaedis develops RTAD technology for stable biologic formulations and flexible drug delivery.
Founded
2022Inaedis develops RTAD technology for stable biologic formulations and flexible drug delivery.
Inaedis performs dehydration at room temperature, addressing the heat sensitivity that complicates conventional drying of biologics. Its platform is designed to create powders or concentrated particle suspensions without introducing a separate high-temperature process.
The company also presents the technology as compatible with existing cGMP spray-drying equipment. The retrofit approach supports development of injectable, inhaled, intranasal, and cold-chain-independent formulations within existing manufacturing infrastructure.
Source: inaedis.com
Inaedis is pursuing formulation problems that constrain biologic storage, concentration, and delivery. Its stated applications include reducing cold-chain dependence, preparing highly concentrated antibody formulations, and enabling pulmonary or nasal administration.
The commercial opportunity spans drug developers and manufacturers that already use regulated spray-drying infrastructure. Progress depends on demonstrating stability, delivery performance, and manufacturability for individual biologic programs within the requirements of their development pathways.
Source: inaedis.com
Inaedis develops room-temperature aerosol dehydration technology for sensitive biologic drugs and vaccines. The process converts liquid formulations into powders or particle suspensions while limiting heat exposure that can damage complex molecules.
The platform supports high-concentration monoclonal antibodies, cold-chain-free biologics, and inhaled or intranasal products. Inaedis says the process can use existing cGMP spray-drying infrastructure, giving manufacturers a path to test it within established production systems.
Source: inaedis.com